LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

AstraZeneca PLC ADR

Slēgts

72.9 0.84

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

72.29

Max

73.15

Galvenie mērījumi

By Trading Economics

Ienākumi

1.7B

3.4B

Pārdošana

-1.3B

14B

P/E

Sektora vidējais

29.004

51.198

EPS

0.934

Dividenžu ienesīgums

2.15

Peļņas marža

25.037

Darbinieki

94,300

EBITDA

610M

5B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+20.44% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.15%

2.40%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

7.5B

224B

Iepriekšējā atvēršanas cena

72.06

Iepriekšējā slēgšanas cena

72.9

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

AstraZeneca PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. maijs 09:36 UTC

Galvenie tirgus virzītāji

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

2025. g. 29. apr. 10:14 UTC

Peļņas

Correction to AstraZeneca Update

2025. g. 29. apr. 09:15 UTC

Peļņas

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

2025. g. 29. apr. 08:12 UTC

Peļņas

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

2025. g. 29. apr. 06:32 UTC

Peļņas

AstraZeneca Sales, Earnings Rise

2025. g. 24. marts 03:15 UTC

Galvenie tirgus virzītāji

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

2025. g. 28. maijs 18:09 UTC

Peļņas

Heart Disease Could Be a Goner When These New -2-

2025. g. 28. maijs 18:09 UTC

Peļņas

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

2025. g. 20. maijs 06:09 UTC

Iegādes, apvienošanās, pārņemšana

AstraZeneca Completes Acquisition of EsoBiotec

2025. g. 12. maijs 12:07 UTC

Tirgus saruna

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

2025. g. 12. maijs 07:20 UTC

Tirgus saruna

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

2025. g. 8. maijs 15:20 UTC

Peļņas

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

2025. g. 29. apr. 13:09 UTC

Tirgus saruna
Peļņas

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

2025. g. 29. apr. 08:04 UTC

Tirgus saruna
Peļņas

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

2025. g. 29. apr. 06:05 UTC

Peļņas

AstraZeneca 1Q Core EPS $2.49

2025. g. 29. apr. 06:04 UTC

Peļņas

AstraZeneca 1Q Net Pft $2.92B

2025. g. 29. apr. 06:02 UTC

Peļņas

AstraZeneca: Committed to Further Invest and Grow in the U.S.

2025. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca 1Q Core EPS Consensus Was $2.27

2025. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca 1Q Revenue Consensus Was $13.80B

2025. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca Backs 2025 View

2025. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca PLC 1Q EPS $1.87

2025. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca PLC 1Q Rev $13.59B

2025. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca PLC 1Q Oper Pft $3.67B

2025. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca PLC 1Q Pretax Pft $3.4B

2025. g. 15. apr. 09:55 UTC

Tirgus saruna

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2025. g. 9. apr. 07:23 UTC

Tirgus saruna

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

2025. g. 3. apr. 08:41 UTC

Tirgus saruna

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

2025. g. 3. apr. 08:36 UTC

Tirgus saruna

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

2025. g. 3. apr. 07:51 UTC

Tirgus saruna

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2025. g. 31. marts 09:31 UTC

Karstas akcijas

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

Salīdzinājums

Cenas izmaiņa

AstraZeneca PLC ADR Prognoze

Cenas mērķis

By TipRanks

20.44% augšup

Prognoze 12 mēnešiem

Vidējais 87.14 USD  20.44%

Augstākais 97 USD

Zemākais 75 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AstraZeneca PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

7

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 69.55Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.